FACSIMILE COVER SHEET CONFIDENTIAL AND PRIVILEGED

RECEIVED GENTRAL FAX CENTER



APR 2 1 2004

101 Jefferson Drive Menlo Park, CA 94025-1114 PHONE: 650.838.4300 FAX: 650.838.4350

DATE: <u>April 21, 2004</u> COVER SHEET & <u>1</u> PAGE(S)			FAX: 650.838.4350 www.perkinscole.com
ORIGINAL DOCUMENT(S) WILL	BE: SENT TO YOU	HELD IN OUR FILES	
SENDER:		TELEPHONE:	FACSIMILE:
LeeAnn Gorthey		650-838-4403	650-838-4350
RECIPIENT:	OMPANY:	TELEPHONE:	FACSIMILE:
Examiner J. Epps-Ford	USPTO	(571) 272-0757	(571)273-0757
	Art Unit 1635		

RE: US Serial No. 09/826,519

Atty Docket No. 1565.006 (52456.8017.US01)

Dear Examiner Epps-Ford,

In response to your telephone request this morning, I have enclosed a listing of the pending claims in the above-referenced application, as of the last amendment to the claims (which was filed on February 11, 2003). You are correct in that there are now three claims pending. Please let me know if you need anything further.

Best regards.

LeeAnn Gorthey, Ph.D.

Patent Agent

Perkins Coie LLP Reg. No. 37,337

This Fax contains confidential, privileged information intended only for the intended addressee. Do not read, copy or disseminate it unless you are the intended addressee. If you have received this Fax in error, please email it back to the sender at perkinscole.com and delete it from your system or call us (collect) immediately at 650.838.4300, and mail the original Fax to Perkins Coie LLP, 101 Jefferson Drive, Menlo Park, CA 94025-1114.

Status of claims in USSN 09/826,519 per response filed February 11, 2003

1-7. (Cancelled)

8. (Previously presented) A chimeric oligonucleotide having the formula $5'-W-X^1-Y-X^2-Z-3'$, wherein

W represents a 5'-O-alkyl nucleotide;

each of X¹ and X² represents a block of seven to twelve phosphodiester-linked 2'-O-alkyl ribonucleotides;

Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides; and Z represents a blocking group effective to block nuclease activity at the 3' end of the oligonucleotide; and

X¹—Y—X² has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 9 and 10.

9-21. (Cancelled)

- 22. (New) The oligonucleotide of claim 8, wherein X¹—Y—X² has the nucleotide sequence SEQ ID NO: 9.
- 23. (New) The oligonucleotide of claim 8, wherein X¹—Y—X² has the nucleotide sequence SEQ ID NO: 10.